18.06.2023, 1915 Zeichen
Marinomed: Marinomed Biotech AG announced the introduction of a new Carragelose eye drop product (MAM-1001-3), expanding the range of the marketed Carragelose OTC portfolio. The product has a valid certification under the Medical Device Directive (MDD) and is currently being prepared for marketing. “The introduction of Carragelose eye drops is a logical addition to our current OTC portfolio. This asset has an upright certification and is ready for partnering and marketing, thus will be generating revenues in the near to medium term,” explains Andreas Grassauer, CEO of Marinomed. “The product is intended to provide relief for dry eyes. Carragelose has excellent moisturizing properties and an outstanding safety profile. In addition, Carragelose is well known for its virus-blocking effectiveness.” With a first partnership for the eye drops already in place, a market launch in Austria is targeted for the first half of 2024.
Marinomed Biotech: weekly performance:
DO & CO: Business year 2022/2023 is by far the strongest in terms of revenue in DO & CO's history. With revenue of € 1,419.35m (PY: € 705.20m) the catering company has doubled its revenue compared to the previous year. The EBITDA of the DO & CO group amounts to € 143.33m (PY: € 96.34m). Consolidated earnings before interest and tax (EBIT) of the DO & CO group amounted to € 85.71m, € 43.31m higher than in the previous year. Net result tripled in business year 2022/2023 to € 33.64m (PY: € 11.00m). "Due to high demand in all its divisions, DO & CO faced the challenge of acquiring new employees in all business divisions. DO & CO is proud to have hired above 3,000 new employees in the business year under review, each of whom has their own unique personality and a passion for hospitality", the company stated.
DO&CO: weekly performance:
(From the 21st Austria weekly https://www.boerse-social.com/21staustria (15/06/2023)
kapitalmarkt-stimme.at daily voice: ATX TR zum 35er heute mit schnellstem 1000er-Marken-Sprung ever und der WBI ist über 2000!
Aktien auf dem Radar:UBM, Polytec Group, Amag, RHI Magnesita, Austriacard Holdings AG, SBO, ATX, ATX Prime, ATX TR, ATX NTR, Bawag, Mayr-Melnhof, Lenzing, voestalpine, Frequentis, Rosgix, AT&S, Palfinger, OMV, Kapsch TrafficCom, Agrana, Gurktaler AG VZ, SW Umwelttechnik, Wolford, Warimpex, Zumtobel, Pierer Mobility, FACC, Addiko Bank, Marinomed Biotech, Oberbank AG Stamm.
Strabag
Strabag SE ist ein europäischer Technologiekonzern für Baudienstleistungen. Das Angebot umfasst sämtliche Bereiche der Bauindustrie und deckt die gesamte Bauwertschöpfungskette ab. Durch das Engagement der knapp 72.000 MitarbeiterInnen erwirtschaftet das Unternehmen jährlich eine Leistung von rund 14 Mrd. Euro (Stand 06/17).
>> Besuchen Sie 62 weitere Partner auf boerse-social.com/partner
Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab.
Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.
Newsletter abonnieren
Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)
per Newsletter erhalten